RxDoctor Payments Data

Lindsey Mosel, MD

Family Medicine · Scottsbluff, NENPI 1336467364

Payments from drug & device makers

$1,427in general payments, 2019–2025

Across 77 payments — averaging $18.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$322
  • AstraZeneca$267
  • Merck$146
  • Mylan Specialty L.p.$105
  • Takeda Pharmaceuticals U.S.A., Inc.$101
  • Novartis$95
  • plus $391 from 13 others

What the payments were for

  • Food & beverage$1,421100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,427 in reported general payments places this provider in the 65th percentile of 981 family medicine providers in Nebraska.

See all family medicine providers in Nebraska

Medicare billing

Part B allowed, 2024
$196,057
Medicare patients
556
Services billed
8,245

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban293$154,426
OzempicSemaglutide48$62,691
MounjaroTirzepatide59$58,963
RybelsusSemaglutide33$50,877
JardianceEmpagliflozin47$46,156
FarxigaDapagliflozin Propanediol44$39,480
TrulicityDulaglutide25$29,256
MyrbetriqMirabegron48$22,046
XareltoRivaroxaban34$20,666
ArexvyRsvpref3 Antigen/As01e/Pf54$16,769
ShingrixVaricella-Zoster Ge/As01b/Pf63$14,164
Breo ElliptaFluticasone/Vilanterol30$13,788
Tresiba Flextouch U-200Insulin Degludec21$13,458
Incruse ElliptaUmeclidinium Bromide28$10,248
JanuviaSitagliptin Phosphate11$9,965

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$83$88,21884 claims
AstraZenecaFarxiga, Bevespi Aerosphere, Symbicort, Pulmicort Flexhaler$267$54,14092 claims
MerckJanuvia, Dulera$146$15,12526 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 981 family medicine providers in Nebraska.

Other family medicine in Scottsbluff

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →